These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 34221537)

  • 1. Vitamins and non-alcoholic fatty liver disease: A Molecular Insight
    Raza S; Tewari A; Rajak S; Sinha RA
    Liver Res; 2021 Jun; 5(2):62-71. PubMed ID: 34221537
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vitamin B
    Tripathi M; Singh BK; Zhou J; Tikno K; Widjaja A; Sandireddy R; Arul K; Abdul Ghani SAB; Bee GGB; Wong KA; Pei HJ; Shekeran SG; Sinha RA; Singh MK; Cook SA; Suzuki A; Lim TR; Cheah CC; Wang J; Xiao RP; Zhang X; Chow PKH; Yen PM
    J Hepatol; 2022 Nov; 77(5):1246-1255. PubMed ID: 35820507
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Role of Vitamins in Non-Alcoholic Fatty Liver Disease: A Systematic Review.
    Abe RAM; Masroor A; Khorochkov A; Prieto J; Singh KB; Nnadozie MC; Abdal M; Shrestha N; Mohammed L
    Cureus; 2021 Aug; 13(8):e16855. PubMed ID: 34522493
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Association between Non-Alcoholic Fatty Liver Disease (NAFLD) and Advanced Fibrosis with Serological Vitamin B12 Markers: Results from the NHANES 1999-2004.
    Li L; Huang Q; Yang L; Zhang R; Gao L; Han X; Ji L; Zou X
    Nutrients; 2022 Mar; 14(6):. PubMed ID: 35334881
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Role of Vitamins in the Pathogenesis of Non-alcoholic Fatty Liver Disease.
    Li J; Cordero P; Nguyen V; Oben JA
    Integr Med Insights; 2016; 11():19-25. PubMed ID: 27147819
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association between vitamin D and non-alcoholic fatty liver disease/non-alcoholic steatohepatitis: results from a meta-analysis.
    Wang X; Li W; Zhang Y; Yang Y; Qin G
    Int J Clin Exp Med; 2015; 8(10):17221-34. PubMed ID: 26770315
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Single-Cell Data Analysis Reveals Critical Hepatic Cells Subpopulations in the Progression of Non-alcoholic Fatty Liver Disease to Non-Alcoholic Steatohepatitis.
    Zhao C; Ji G; Zhao X; Ma T; Li Y; Wu W; Zhou L
    Comb Chem High Throughput Screen; 2024 May; ():. PubMed ID: 38803181
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatocyte vitamin D receptor regulates lipid metabolism and mediates experimental diet-induced steatosis.
    Bozic M; Guzmán C; Benet M; Sánchez-Campos S; García-Monzón C; Gari E; Gatius S; Valdivielso JM; Jover R
    J Hepatol; 2016 Oct; 65(4):748-757. PubMed ID: 27245430
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disturbed Vitamin A Metabolism in Non-Alcoholic Fatty Liver Disease (NAFLD).
    Saeed A; Dullaart RPF; Schreuder TCMA; Blokzijl H; Faber KN
    Nutrients; 2017 Dec; 10(1):. PubMed ID: 29286303
    [TBL] [Abstract][Full Text] [Related]  

  • 10. From sugar to liver fat and public health: systems biology driven studies in understanding non-alcoholic fatty liver disease pathogenesis.
    Moore JB
    Proc Nutr Soc; 2019 Aug; 78(3):290-304. PubMed ID: 30924429
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Possible Hepatoprotective Effect of Tocotrienol-Rich Fraction Vitamin E in Non-alcoholic Fatty Liver Disease in Obese Children and Adolescents.
    Al-Baiaty FDR; Ismail A; Abdul Latiff Z; Muhammad Nawawi KN; Raja Ali RA; Mokhtar NM
    Front Pediatr; 2021; 9():667247. PubMed ID: 34307250
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypovitaminosis D is associated with increased whole body fat mass and greater severity of non-alcoholic fatty liver disease.
    Dasarathy J; Periyalwar P; Allampati S; Bhinder V; Hawkins C; Brandt P; Khiyami A; McCullough AJ; Dasarathy S
    Liver Int; 2014 Jul; 34(6):e118-27. PubMed ID: 24118743
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A narrative review on effects of vitamin D on main risk factors and severity of Non-Alcoholic Fatty Liver Disease.
    Sangouni AA; Ghavamzadeh S; Jamalzehi A
    Diabetes Metab Syndr; 2019; 13(3):2260-2265. PubMed ID: 31235166
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatocyte nuclear factor 4α in the pathogenesis of non-alcoholic fatty liver disease.
    Pan X; Zhang Y
    Chin Med J (Engl); 2022 May; 135(10):1172-1181. PubMed ID: 35191422
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of nutraceuticals for the treatment of non-alcoholic fatty liver disease.
    Del Ben M; Polimeni L; Baratta F; Pastori D; Angelico F
    Br J Clin Pharmacol; 2017 Jan; 83(1):88-95. PubMed ID: 26852185
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH)-related liver fibrosis: mechanisms, treatment and prevention.
    Tacke F; Weiskirchen R
    Ann Transl Med; 2021 Apr; 9(8):729. PubMed ID: 33987427
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolic signatures across the full spectrum of non-alcoholic fatty liver disease.
    McGlinchey AJ; Govaere O; Geng D; Ratziu V; Allison M; Bousier J; Petta S; de Oliviera C; Bugianesi E; Schattenberg JM; Daly AK; Hyötyläinen T; Anstee QM; Orešič M
    JHEP Rep; 2022 May; 4(5):100477. PubMed ID: 35434590
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationship of vitamin D with insulin resistance and disease severity in non-alcoholic steatohepatitis.
    Bril F; Maximos M; Portillo-Sanchez P; Biernacki D; Lomonaco R; Subbarayan S; Correa M; Lo M; Suman A; Cusi K
    J Hepatol; 2015 Feb; 62(2):405-11. PubMed ID: 25195551
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Defining the serum proteomic signature of hepatic steatosis, inflammation, ballooning and fibrosis in non-alcoholic fatty liver disease.
    Sanyal AJ; Williams SA; Lavine JE; Neuschwander-Tetri BA; Alexander L; Ostroff R; Biegel H; Kowdley KV; Chalasani N; Dasarathy S; Diehl AM; Loomba R; Hameed B; Behling C; Kleiner DE; Karpen SJ; Williams J; Jia Y; Yates KP; Tonascia J
    J Hepatol; 2023 Apr; 78(4):693-703. PubMed ID: 36528237
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Spatial molecular and cellular determinants of STAT3 activation in liver fibrosis progression in non-alcoholic fatty liver disease.
    Jiao J; Sanchez JI; Saldarriaga OA; Solis LM; Tweardy DJ; Maru DM; Stevenson HL; Beretta L
    JHEP Rep; 2023 Feb; 5(2):100628. PubMed ID: 36687470
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.